Navigation Links
Ranbaxy Launches Omeprazole 40 mg Capsules
Date:7/28/2008

GURGAON, India and PRINCETON, N.J., July 28 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India announced today that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40 mg Capsules in the U.S. healthcare system. Omeprazole 40 mg is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. The most common side effects of Prilosec(R) are headache, diarrhea and abdominal pain. Prilosec(R) 40 mg had sales in the U.S. market of $204.2 million (IMS: March 2008 MAT).

"We welcome the opportunity to market an authorized generic of Omeprazole 40 mg capsules that will be commercialized immediately to all classes of trade in the U.S. healthcare system under the Ranbaxy label," said Jim Meehan, Vice President of Sales and Distribution for RPI. "We will offer this product as an affordable and accessible generic formulation to patients requiring this medication."

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an ex
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
2. Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
3. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
5. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
6. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
7. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
8. GeneNews launches worlds first blood test for colorectal cancer screening
9. Norgen Biotek Corp. Launches Four New Kits for the Purification of RNA and DNA from Plants and Fungi
10. Health Market Science Launches Clinical Investigators(TM)
11. SAFC Supply Solutions Launches REACH-Compliant Products and Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 Not long ... E&L studies should be performed late in the development ... known. But current regulatory trends suggest that, like many ... the rise. In recent years, multiple drug sponsors have ... or address specific questions during phase I/II. It’s not ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... improve the health of your heart, researchers have discovered. ... a standard TENS machine like those designed to relieve ... the small raised flap at the front of the ... The stimulation changed the influence of the nervous system ... can drive failing hearts too hard. , Professor Jim ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2'Tickling' your ear could be good for your heart 2EQ-5D™ Assessment Now Available for iPad 2
... Oct. 28 BioStorage Technologies, a global leader ... storage for the pharmaceutical and biotechnology industries, announces ... of global sales.   Atwood will ... and leadership of global sales initiatives. His key ...
... Calif., Oct. 28 ChromaDex Corporation (OTC Bulletin Board: ... of phytochemical and botanical reference standards and the creation ... appointed William F. Spengler to President of the Company, ... and diversified background to the position, having held leadership ...
... (Nasdaq: UTHR ) today announced its results of operations ... for the third quarter of 2010 were $171.0 million, up from ... the third quarter of 2010 was $39.7 million, or $0.70 per ... per basic share, for the same quarter in 2009. Gross margin ...
Cached Biology Technology:BioStorage Technologies Appoints New Vice President of Global Sales 2ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President 2ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President 3United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 2United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 3United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 4United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 5United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 6United Therapeutics Corporation Reports Third Quarter 2010 Financial Results 7
(Date:8/19/2014)... New Rochelle, August 19, 2014A new ovoid structure discovered ... iron-rich clay, contains a variety of minerals, and shows ... with resulting melting of the permafrost and mixing of ... a broad range of analytical studies to determine the ... hypotheses for how this ovoid formed, point to the ...
(Date:8/19/2014)... pain, but its effect on pain following brachial ... study reported on the Neural Regeneration Research ... of an avulsion injury to the left brachial ... were given electroacupuncture stimulation at bilateral Quchi (LI11), ... electroacupuncture therapy, chronic neuropathic pain in the rats, ...
(Date:8/19/2014)... 2014 Smart Technology Sector improves ... as latest developments, ad campaigns and partnerships are announced: ... EBAY ), Amazon.com Inc. (NASDAQ: AMZN ), ... (NASDAQ: GOOG ) and Mastercard Incorporated (NYSE: ... authentication company focused on the growing m-commerce market releases ...
Breaking Biology News(10 mins):Life on Mars? Implications of a newly discovered mineral-rich structure 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7
... bathrooms may become a thing of the past with new ... at the University of New South Wales are developing new ... hospitals and the home. , Led by Professor ... for Functional Nanomaterials, a research team is studying tiny particles ...
... have made nisin, a natural antibiotic used for more than ... the first time using nature's toolbox. They also identified the ... its unique biological power. , The work -- published in ... the almost magical manner in which nisin is made in ...
... of malaria up to five months in advance has been developed ... uses predictions of climate variability to indicate the level of risk ... peak malaria season ?the earliest point at which predictions have ever ... providers in preventing and controlling the disease. , Malaria ...
Cached Biology News:Creation of antibiotic in test tube holds promise for better antibiotics 2Scientists develop malaria forecasting tool to predict disease risk 2
... tissue panels are designed for studying ... or proteins of interest in different ... positively charged glass slides. Total RNA ... identical format, and cDNA from those ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... The T2-02 diaphragm pump features T ... and achieves remarkable performance and efficiency. With ... performance range, T2-02 is ideal for use ... Offers ultra-compact size, long life, and high ...
Biology Products: